Mike J. Pishvaian, MD, PhD

This segment focuses on real-world toxicity management with immune checkpoint inhibitors, particularly nivolumab plus ipilimumab, and how increasing familiarity has shaped clinician comfort and patient outcomes in MSI-H/dMMR mCRC. The discussion opens with reflections on unexpected or rare immune-related adverse events, highligting the heterogeneous and sometimes unpredictable nature of immunotherapy toxicity. Although classic toxicities such as colitis, pneumonitis, hepatitis, and rash are well recognized, panelists note that unusual presentations can occur and require clinical vigilance.

In this segment, the panel addresses a key clinical question in MSI-H/dMMR mCRC: should dual immune checkpoint blockade with nivolumab plus ipilimumab be used universally upfront, or can clinicians safely sequence therapies and reserve CTLA-4 inhibition for later lines?

Experts discuss the evolving role of ctDNA in managing MSI-high cancer patients, emphasizing non-operative approaches and improved treatment strategies.

Experts discuss recent advancements in precision care for unresectable metastatic colorectal cancer, focusing on innovative treatment strategies and biomarker roles.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the prevalence of RAS mutations in pancreatic ductal adenocarcinoma.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, detail the continued interest in RAS inhibition for pancreatic ductal adenocarcinoma.

Michael Jon Pishvaian, MD, PhD, discusses the clinical implications of the phase 3 RATIONALE 306 trial and the adverse effects associated with immunotherapy in patients with advanced esophageal squamous cell carcinoma.

Michael J. Pishvaian, MD, PhD, discusses the FDA approval of the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for the treatment of patients with hepatocellular carcinoma (HCC).